ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023
PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-Analysis.Radiology. Imaging cancer · 2026Pooled it
- Quantitative PSMA PET Biomarkers for Predicting Response toJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Pooled it
- Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- Evaluation of the biodistribution of [EJNMMI research · 2026Article
- Reference tissue uptake of [18F]PSMA-1007 in positron emission tomography of recurrent prostate cancer.European radiology · 2026Article
- Baseline PSMA PET/CT Biomarkers for Patient Selection in [Pharmaceuticals (Basel, Switzerland) · 2026Review
- PET-imaging derived prognostic factors for prostate cancer patients with visceral metastases receiving [European journal of nuclear medicine and molecular imaging · 2026Article
- PSMA PET/CT-Derived Indicators and Outcomes After [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- The role of multimodality imaging in selection, response assessment, and follow-up of patients receivingInsights into imaging · 2026Article
- Predicting PSA50 response to [Formula: see text]Lu-PSMA therapy using machine learning and automated total tumor volume.EJNMMI physics · 2025Article
- PSMA-1-DOTA Potentially for Effective Targeted Radioligand Therapy of Prostate Cancer.Molecular imaging and biology · 2025Article
- A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients.European journal of nuclear medicine and molecular imaging · 2025Article
- Visual and QuantitativeMolecular imaging and biology · 2025Article
- Radionuclides Landscape in Prostate Cancer Theranostics.International journal of molecular sciences · 2025Review
- PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy.Targeted oncology · 2025Review
- [Role of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) in staging].Urologie (Heidelberg, Germany) · 2025Review
- Study of predictive factors for response toFrontiers in medicine · 2025Article
- Article
- Searching for Protein Off-Targets of Prostate-Specific Membrane Antigen-Targeting Radioligands in the Salivary Glands.Cancer biotherapy & radiopharmaceuticals · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy can improve the outcome of patients with advanced metastatic castration-resistant prostate cancer, but patients do not respond uniformly. We hypothesized that using the salivary glands as a reference organ can enable selective patient stratification. We aimed to establish a PSMA PET tumor-to-salivary gland ratio (PSG score) to predict outcomes after [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.